Immune checkpoint inhibitor-related acral vasculitis

Commentary on « Ipilimumab induced vasculitis » by Padda A. et al., J Immunother Cancer. 2018;6:12. The authors diagnosed a small vessel vasculitis following treatment with anti-CTLA-4 (ipilimumab) for a resected stage III B/C melanoma. We report a similar case of acral vasculitis occurring with a c...

Descripción completa

Detalles Bibliográficos
Autores principales: Comont, Thibault, Sibaud, Vincent, Mourey, Loïc, Cougoul, Pierre, Beyne-Rauzy, Odile
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240222/
https://www.ncbi.nlm.nih.gov/pubmed/30446009
http://dx.doi.org/10.1186/s40425-018-0443-6
_version_ 1783371599224766464
author Comont, Thibault
Sibaud, Vincent
Mourey, Loïc
Cougoul, Pierre
Beyne-Rauzy, Odile
author_facet Comont, Thibault
Sibaud, Vincent
Mourey, Loïc
Cougoul, Pierre
Beyne-Rauzy, Odile
author_sort Comont, Thibault
collection PubMed
description Commentary on « Ipilimumab induced vasculitis » by Padda A. et al., J Immunother Cancer. 2018;6:12. The authors diagnosed a small vessel vasculitis following treatment with anti-CTLA-4 (ipilimumab) for a resected stage III B/C melanoma. We report a similar case of acral vasculitis occurring with a combination of anti-CTLA-4 (tremelimumab) and anti-PD-L1 (durvalumab) prescribed for the management of a metastatic urothelial bladder cancer. In contrast to Padda A. et al., we observed a significant improvement with oral corticosteroids.
format Online
Article
Text
id pubmed-6240222
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62402222018-11-26 Immune checkpoint inhibitor-related acral vasculitis Comont, Thibault Sibaud, Vincent Mourey, Loïc Cougoul, Pierre Beyne-Rauzy, Odile J Immunother Cancer Commentary Commentary on « Ipilimumab induced vasculitis » by Padda A. et al., J Immunother Cancer. 2018;6:12. The authors diagnosed a small vessel vasculitis following treatment with anti-CTLA-4 (ipilimumab) for a resected stage III B/C melanoma. We report a similar case of acral vasculitis occurring with a combination of anti-CTLA-4 (tremelimumab) and anti-PD-L1 (durvalumab) prescribed for the management of a metastatic urothelial bladder cancer. In contrast to Padda A. et al., we observed a significant improvement with oral corticosteroids. BioMed Central 2018-11-16 /pmc/articles/PMC6240222/ /pubmed/30446009 http://dx.doi.org/10.1186/s40425-018-0443-6 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Commentary
Comont, Thibault
Sibaud, Vincent
Mourey, Loïc
Cougoul, Pierre
Beyne-Rauzy, Odile
Immune checkpoint inhibitor-related acral vasculitis
title Immune checkpoint inhibitor-related acral vasculitis
title_full Immune checkpoint inhibitor-related acral vasculitis
title_fullStr Immune checkpoint inhibitor-related acral vasculitis
title_full_unstemmed Immune checkpoint inhibitor-related acral vasculitis
title_short Immune checkpoint inhibitor-related acral vasculitis
title_sort immune checkpoint inhibitor-related acral vasculitis
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240222/
https://www.ncbi.nlm.nih.gov/pubmed/30446009
http://dx.doi.org/10.1186/s40425-018-0443-6
work_keys_str_mv AT comontthibault immunecheckpointinhibitorrelatedacralvasculitis
AT sibaudvincent immunecheckpointinhibitorrelatedacralvasculitis
AT moureyloic immunecheckpointinhibitorrelatedacralvasculitis
AT cougoulpierre immunecheckpointinhibitorrelatedacralvasculitis
AT beynerauzyodile immunecheckpointinhibitorrelatedacralvasculitis

Ejemplares similares